protocolSection,resultsSection,documentSection,derivedSection,hasResults
"{'identificationModule': {'nctId': 'NCT00003042', 'orgStudyIdInfo': {'id': '96139'}, 'secondaryIdInfos': [{'id': 'P30CA033572', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/P30CA033572'}, {'id': 'CHNMC-96139'}, {'id': 'NCI-G97-1288'}, {'id': 'CDR0000065672', 'type': 'REGISTRY', 'domain': 'NCI PDQ'}], 'organization': {'fullName': 'City of Hope Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer', 'officialTitle': 'Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '1997-05-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2010-02-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2025-12-29', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '1999-11-01', 'studyFirstSubmitQcDate': '2003-01-26', 'studyFirstPostDateStruct': {'date': '2003-01-27', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2021-03-12', 'resultsFirstSubmitQcDate': '2021-03-12', 'resultsFirstPostDateStruct': {'date': '2021-04-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-17', 'lastUpdatePostDateStruct': {'date': '2025-03-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'City of Hope Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.\n\nPURPOSE: This phase II trial is studying how well chemotherapy and stem cell transplantation work in treating patients with stage IIIB breast cancer.', 'detailedDescription': 'OBJECTIVES:\n\n* Determine the effectiveness of neoadjuvant dose intensive sequential chemotherapy, followed by surgical resection, adjuvant therapy, and tandem high dose chemotherapy and stem cell rescue in patients with inflammatory stage IIIB breast cancer.\n* Determine the clinical and pathological remission rate (complete, partial, and overall) following neoadjuvant dose dependent sequential chemotherapy in patients with inflammatory stage IIIB breast cancer.\n* Determine the relapse and survival rate of these patients with the above therapy.\n* Determine the potential correlations between inflammatory features and hereditary background.\n\nOUTLINE: Patients are stratified according to those who have had no more than 1 cycle of neoadjuvant chemotherapy (stratum 1) and those who have had more than 1 cycle of neoadjuvant chemotherapy and/or modified radical mastectomy (stratum 2).\n\nPatients in stratum 1 receive doxorubicin IV over 96 hours on days 1-4, 15-19, and 29-32. Paclitaxel is infused over 96 hours on days 43-47 and 57-60. Filgrastim (G-CSF) is administered on days 5-10, 20-25, 33-38, 48-55, and 61-68, and beyond if the granulocyte count is less than 1000/mm\\^3. A modified radical mastectomy is performed between days 70 and 80. All stratum 1 and stratum 2 patients then receive paclitaxel IV for 96 hours on days 100-104, and cyclophosphamide IV on day 121. Filgrastim is administered at one dose on days 105-110 and days 122-127 and at a higher dose on days 110-116 and days 128-135. Stem cells are harvested from the patient on days 113-116 and days 132-135.\n\nHigh-dose chemotherapy is then administered to all patients in the study. Course 1 starts with doxorubicin IV on days -7 to -3. Paclitaxel IV is administered for 24 hours on day -2. Filgrastim is administered by IV on day -1 and continued until the granulocyte count is greater than 1000/mm\\^3 for 3 days. Peripheral stem cells are reinfused on day 0. Course 2 starts 4-6 weeks after the start of course 1 with melphalan and cisplatin being infused on day -11. Filgrastim is administered IV on days -10 to -6. Melphalan and cisplatin are administered again on day -4. Stem cells are infused on day -3 and on day 0. Filgrastim is then administered until the granulocyte count is at least 1000/mm\\^3 for 3 days.\n\nRadiation therapy is started 4-7 weeks after the beginning of course 2. Tamoxifen is started within 2 weeks of discharge following course 2 in patients with hormone receptor positive tumors.\n\nPatients are followed every 3 months for two years and then annually for the next three years.\n\nPROJECTED ACCRUAL: Approximately 60 patients will be accrued, at a rate of about 15 per year.'}, 'conditionsModule': {'conditions': ['Breast Cancer'], 'keywords': ['stage IIIB breast cancer', 'inflammatory breast cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 41, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1 cycle of neoadjuvant chemotherapy', 'type': 'EXPERIMENTAL', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.', 'interventionNames': ['Biological: filgrastim', 'Drug: cisplatin', 'Drug: cyclophosphamide', 'Drug: doxorubicin hydrochloride', 'Drug: melphalan', 'Drug: mesna', 'Drug: paclitaxel', 'Drug: tamoxifen citrate', 'Procedure: bone marrow ablation with stem cell support', 'Procedure: conventional surgery', 'Procedure: peripheral blood stem cell transplantation']}, {'label': 'More than 1 cycle of neoadjuvant chemotherapy', 'type': 'EXPERIMENTAL', 'description': 'Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.', 'interventionNames': ['Biological: filgrastim', 'Drug: cisplatin', 'Drug: doxorubicin hydrochloride', 'Drug: melphalan', 'Drug: mesna', 'Drug: paclitaxel', 'Drug: tamoxifen citrate', 'Procedure: bone marrow ablation with stem cell support', 'Procedure: peripheral blood stem cell transplantation']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'filgrastim', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'cisplatin', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'cyclophosphamide', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'doxorubicin hydrochloride', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'melphalan', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'mesna', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'paclitaxel', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'DRUG', 'name': 'tamoxifen citrate', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'PROCEDURE', 'name': 'bone marrow ablation with stem cell support', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}, {'type': 'PROCEDURE', 'name': 'conventional surgery', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy']}, {'type': 'PROCEDURE', 'name': 'peripheral blood stem cell transplantation', 'armGroupLabels': ['1 cycle of neoadjuvant chemotherapy', 'More than 1 cycle of neoadjuvant chemotherapy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Three-year Relapse-free Survival', 'description': 'Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.', 'timeFrame': 'From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.'}, {'measure': 'Five-year Overall Survival', 'description': 'Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.', 'timeFrame': 'From date of mastectomy until date of death, 5 years post mastectomy.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\n* Histologically proven stage IIIB breast cancer with dermal/epidermal invasion or clinical features of inflammation, erythema, pain or hypersensitivity, edema, or thickening of the skin\n* Diagnosis within the past 6 months\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 60 and under\n\nPerformance status:\n\n* Karnofsky 80-100%\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin less than 1.5 mg/dL\n* SGOT or SGPT no greater than 1.5 times the upper limit of normal\n\nRenal:\n\n* Creatinine less than 1.2 mg/dL\n* Creatinine clearance at least 80 mL/min\n* No history of hemorrhagic cystitis\n\nCardiovascular:\n\n* Left ventricular fraction at least 55% on MUGA scan\n* No previous valvular heart disease or arrhythmia\n\nPulmonary:\n\n* FEV\\_1 at least 60% predicted\n* Room air pO\\_2 greater than 85 mmHg\n* Room air pCO\\_2 no greater than 43 mmHg\n* DLCO at least 60% of the lower limit of predicted value\n\nOther:\n\n* No history of malignant disease in the past 5 years, except for squamous or basal cell skin cancer and stage I or in situ cervical cancer\n* No organic CNS dysfunction\n* Not pregnant\n* No known and potentially disabling psychosocial history\n* Not positive for hepatitis B or HIV\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Stratum 1:\n\n  * No more than one cycle of chemotherapy\n* Stratum 2:\n\n  * No greater than 225 mg/m\\^2 doxorubicin and no greater than 250 mg/m\\^2 paclitaxel during previous chemotherapy\n\nEndocrine therapy:\n\n* Not specified\n\nRadiotherapy:\n\n* No prior radiation to the left chest wall\n\nSurgery:\n\n* Modified radical mastectomy allowed', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '60 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'George Somlo, MD', 'affiliation': 'City of Hope Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'City of Hope Comprehensive Cancer Center', 'city': 'Duarte', 'state': 'California', 'zip': '91010-3000', 'country': 'United States', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}]}}","{'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ncyclophosphamide\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nconventional surgery\n\nperipheral blood stem cell transplantation'}, {'id': 'FG001', 'title': 'High-dose Chemo With Rescue', 'description': 'Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nperipheral blood stem cell transplantation'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ncyclophosphamide\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nconventional surgery\n\nperipheral blood stem cell transplantation'}, {'id': 'BG001', 'title': 'High-dose Chemo With Rescue', 'description': 'Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nperipheral blood stem cell transplantation'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '14'}, {'groupId': 'BG001', 'value': '27'}, {'groupId': 'BG002', 'value': '41'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEDIAN', 'dispersionType': 'FULL_RANGE', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '49', 'lowerLimit': '30', 'upperLimit': '61'}, {'groupId': 'BG001', 'value': '50', 'lowerLimit': '34', 'upperLimit': '61'}, {'groupId': 'BG002', 'value': '50', 'lowerLimit': '30', 'upperLimit': '61'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '14'}, {'groupId': 'BG001', 'value': '27'}, {'groupId': 'BG002', 'value': '41'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Race/Ethnicity, Customized', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'White', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '13'}, {'groupId': 'BG001', 'value': '25'}, {'groupId': 'BG002', 'value': '38'}]}]}, {'title': 'Hispanic', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '2'}]}]}, {'title': 'Black', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '14'}, {'groupId': 'BG001', 'value': '27'}, {'groupId': 'BG002', 'value': '41'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Three-year Relapse-free Survival', 'description': 'Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.', 'groups': [{'id': 'OG000', 'title': 'Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ncyclophosphamide\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nconventional surgery\n\nperipheral blood stem cell transplantation'}, {'id': 'OG001', 'title': 'High-dose Chemo With Rescue', 'description': 'Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nperipheral blood stem cell transplantation'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '14'}, {'groupId': 'OG001', 'value': '27'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '61.5', 'lowerLimit': '30.8', 'upperLimit': '81.8'}, {'groupId': 'OG001', 'value': '77.8', 'lowerLimit': '57.1', 'upperLimit': '89.3'}]}]}]}, {'type': 'PRIMARY', 'title': 'Five-year Overall Survival', 'description': 'Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'From date of mastectomy until date of death, 5 years post mastectomy.', 'groups': [{'id': 'OG000', 'title': 'Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ncyclophosphamide\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nconventional surgery\n\nperipheral blood stem cell transplantation'}, {'id': 'OG001', 'title': 'High-dose Chemo With Rescue', 'description': 'Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nperipheral blood stem cell transplantation'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '14'}, {'groupId': 'OG001', 'value': '27'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '69.2', 'lowerLimit': '37.3', 'upperLimit': '87.2'}, {'groupId': 'OG001', 'value': '70.4', 'lowerLimit': '49.4', 'upperLimit': '83.9'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': 'Adverse events were assessed during all cycles of chemotherapy treatment (up to 6 months).', 'description': '""Other Adverse Events"" include all events that were not severe adverse events regardless of grade or relation to treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue', 'description': 'Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ncyclophosphamide\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nconventional surgery\n\nperipheral blood stem cell transplantation', 'deathsNumAffected': 10, 'deathsNumAtRisk': 14, 'seriousNumAffected': 0, 'seriousNumAtRisk': 14, 'otherNumAffected': 13, 'otherNumAtRisk': 14}, {'id': 'EG001', 'title': 'High-dose Chemo With Rescue', 'description': 'Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.\n\nfilgrastim\n\ncisplatin\n\ndoxorubicin hydrochloride\n\nmelphalan\n\nmesna\n\npaclitaxel\n\ntamoxifen citrate\n\nbone marrow ablation with stem cell support\n\nperipheral blood stem cell transplantation', 'deathsNumAffected': 14, 'deathsNumAtRisk': 27, 'seriousNumAffected': 2, 'seriousNumAtRisk': 27, 'otherNumAffected': 23, 'otherNumAtRisk': 27}], 'seriousEvents': [{'term': 'Skin infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'meddra10.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Alkalosis', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}], 'otherEvents': [{'term': 'Cerebellar', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Dysrhythmias', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Fluid Retention', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Haematemesis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 27, 'numAffected': 11, 'numAtRisk': 27}]}, {'term': 'Ischemia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Pericardial', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Pulmonary', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Stomatitis', 'organSystem': 'General disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Weight (Food Intake)', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 16, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Clinical Coagulation', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Disseminated intravascular coagulation', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Febrile neutropenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 11, 'numAtRisk': 27}]}, {'term': 'Hemoglobin decreased', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Lymphatic disorder', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Arrhythmia supraventricular', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'EF/CHF', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Left ventricular failure', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 27}]}, {'term': 'Myocardial ischemia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Pericardial effusion', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Sinus bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Sinus tachycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Ventricular arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Ear disorder', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Hearing', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Hearing loss', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Vision', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Abdominal pain', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 16, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 30, 'numAffected': 18, 'numAtRisk': 27}]}, {'term': 'Diarrhea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 18, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 13, 'numAtRisk': 27}]}, {'term': 'Diarrhea (Somlo COH)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Dry mouth', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Dysphagia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Dysphagia, esophagitis, odynophagia (Somlo COH)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Esophagitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Gastrointestinal disorder', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Haematochezia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Incontinence NOS', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Melaena', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Mucositis oral', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 10, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 34, 'numAffected': 18, 'numAtRisk': 27}]}, {'term': 'Nausea (Somlo COH)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Proctitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Stomatitis/phayngitis (Somlo COH)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 10, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 35, 'numAffected': 19, 'numAtRisk': 27}]}, {'term': 'Vomiting (Somlo COH)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Chills', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 14, 'numAffected': 8, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Fever', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Fever (no infection)', 'organSystem': 'General disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 11, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 21, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'General symptom', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Injection site reaction', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 27}]}, {'term': 'Irritability', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Oedema NOS', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 11, 'numAtRisk': 27}]}, {'term': 'Pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Hepatobiliary disease', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Allergy', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Hypersensitivity', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Catheter related infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Infection, Bacterial (COH)', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Wound dehiscence', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'AGC', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Activated partial thromboplastin time prolonged', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Alanine aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Alk Phos (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Alkaline Phosphatase', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Alkaline phosphatase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Amylase', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Aspartate aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Bilirubin', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Bilirubin (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Creatinine', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Creatinine increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 27}]}, {'term': 'HGB/HCT', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 13, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Hyperbilirubinemia', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Hypercholesterolemia', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'INR increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 13, 'numAtRisk': 27}]}, {'term': 'Leukopenia', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Lymphopenia', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Neutrophil count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Neutrophils (ANC) (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 8, 'numAtRisk': 27}]}, {'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 39, 'numAffected': 7, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 53, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Partial Thromboplastin Time', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Platelet count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Platelets', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Platelets (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Prothrombin Time', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'SGOT (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'SGOT/SGT', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'SGPT (Somlo COH)', 'organSystem': 'Investigations', 'sourceVocabulary': 'Somlo', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'WBC', 'organSystem': 'Investigations', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 13, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 27}]}, {'term': 'Weight gain', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Weight loss', 'organSystem': 'Investigations', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Anorexia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Blood bicarbonate decreased', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Dehydration', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypercalcemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Hyperglycemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 12, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 43, 'numAffected': 23, 'numAtRisk': 27}]}, {'term': 'Hypermagnesemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Hyperuricemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypoalbuminemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypocalcemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 12, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 42, 'numAffected': 22, 'numAtRisk': 27}]}, {'term': 'Hypoglycemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Hypokalemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypomagnesemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 17, 'numAffected': 10, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 37, 'numAffected': 21, 'numAtRisk': 27}]}, {'term': 'Hyponatremia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypophosphatemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Arthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Bone pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Joint pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Musculoskeletal disorder', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Myalgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Ataxia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Cortical/State of Consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 20, 'numAffected': 11, 'numAtRisk': 27}]}, {'term': 'Depressed level of consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Extrapyramidal disorder', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 15, 'numAffected': 10, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 29, 'numAffected': 17, 'numAtRisk': 27}]}, {'term': 'Motor Activity', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Neuralgia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Neurological disorder NOS', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Peripheral Nervous System Sensory', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Peripheral motor neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Peripheral sensory neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 12, 'numAtRisk': 27}]}, {'term': 'Speech disorder', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Taste alteration', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Anxiety', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Confusion', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 27}]}, {'term': 'Hallucination NOS', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Ideation', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Insomnia', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Mood', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 10, 'numAtRisk': 27}]}, {'term': 'Personality change', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Blood urine present', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hematuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Proteinuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Urinary frequency', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Urinary retention', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Urine discoloration', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Vaginal hemorrhage', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Allergic rhinitis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Dyspnea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 27}]}, {'term': 'Haemoptysis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Hemorrhage nasal', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 27}]}, {'term': 'Hiccough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Hypoxia', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 27}]}, {'term': 'Pleural effusion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Pneumonitis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Respiratory disorder', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Voice alteration', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Alopecia', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 12, 'numAffected': 6, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 27}]}, {'term': 'Dry skin', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Erythema multiforme', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Extensive Skin Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Local Skin Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 7, 'numAtRisk': 27}]}, {'term': 'Nail disorder', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Petechiae', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 27}]}, {'term': 'Pruritus', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Rash desquamating', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 5, 'numAtRisk': 27}]}, {'term': 'Skin discolouration', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Skin disorder', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 27}]}, {'term': 'Sweating', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 27}]}, {'term': 'Urticaria', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 27}]}, {'term': 'Flushing', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 27}]}, {'term': 'Hemorrhage', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 7, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 29, 'numAffected': 13, 'numAtRisk': 27}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'COH', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 17, 'numAtRisk': 27}]}, {'term': 'Hypotension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'meddra9.0', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 7, 'numAtRisk': 14}, {'groupId': 'EG001', 'numEvents': 24, 'numAffected': 17, 'numAtRisk': 27}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'Paul Frankel, Ph.D.', 'organization': 'City of Hope', 'email': 'pfrankel@coh.org', 'phone': '626-218-5265'}}}","{'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2017-12-21', 'uploadDate': '2021-03-12T12:15', 'filename': 'Prot_SAP_000.pdf', 'size': 3049321}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D058922', 'term': 'Inflammatory Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069585', 'term': 'Filgrastim'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'D008558', 'term': 'Melphalan'}, {'id': 'D015080', 'term': 'Mesna'}, {'id': 'D017239', 'term': 'Paclitaxel'}, {'id': 'D013629', 'term': 'Tamoxifen'}, {'id': 'D036102', 'term': 'Peripheral Blood Stem Cell Transplantation'}], 'ancestors': [{'id': 'D016179', 'term': 'Granulocyte Colony-Stimulating Factor'}, {'id': 'D003115', 'term': 'Colony-Stimulating Factors'}, {'id': 'D006023', 'term': 'Glycoproteins'}, {'id': 'D006001', 'term': 'Glycoconjugates'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D016298', 'term': 'Hematopoietic Cell Growth Factors'}, {'id': 'D016207', 'term': 'Cytokines'}, {'id': 'D036341', 'term': 'Intercellular Signaling Peptides and Proteins'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D001685', 'term': 'Biological Factors'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D010649', 'term': 'Phenylalanine'}, {'id': 'D024322', 'term': 'Amino Acids, Aromatic'}, {'id': 'D000598', 'term': 'Amino Acids, Cyclic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000476', 'term': 'Alkanesulfonates'}, {'id': 'D017738', 'term': 'Alkanesulfonic Acids'}, {'id': 'D000473', 'term': 'Alkanes'}, {'id': 'D006839', 'term': 'Hydrocarbons, Acyclic'}, {'id': 'D013438', 'term': 'Sulfhydryl Compounds'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D013451', 'term': 'Sulfonic Acids'}, {'id': 'D013456', 'term': 'Sulfur Acids'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}, {'id': 'D013267', 'term': 'Stilbenes'}, {'id': 'D001597', 'term': 'Benzylidene Compounds'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D018380', 'term': 'Hematopoietic Stem Cell Transplantation'}, {'id': 'D033581', 'term': 'Stem Cell Transplantation'}, {'id': 'D017690', 'term': 'Cell Transplantation'}, {'id': 'D064987', 'term': 'Cell- and Tissue-Based Therapy'}, {'id': 'D001691', 'term': 'Biological Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D014180', 'term': 'Transplantation'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}]}}",True
"{'identificationModule': {'nctId': 'NCT07065786', 'orgStudyIdInfo': {'id': 'GenTI-uHCC'}, 'organization': {'fullName': 'Zhongda Hospital', 'class': 'OTHER'}, 'briefTitle': 'A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy', 'officialTitle': 'A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-01-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-02-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-07-01', 'studyFirstSubmitQcDate': '2025-07-10', 'studyFirstPostDateStruct': {'date': '2025-07-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-10', 'lastUpdatePostDateStruct': {'date': '2025-07-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Gao-jun Teng', 'investigatorTitle': 'Professor of Radiology Zhongda Hospital, Southeast University', 'investigatorAffiliation': 'Zhongda Hospital'}, 'leadSponsor': {'name': 'Zhongda Hospital', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The entry point of this study is the proposition of ""generative longitudinal prediction,"" which utilizes only pre-treatment imaging to create high-fidelity predictions of post-treatment imaging. This approach effectively overcomes the clinical challenge of acquiring genuine longitudinal follow-up data. This paradigm shift not only tackles the scarcity of longitudinal data but also introduces an innovative method for treatment simulation using digital twins. Clinicians can intuitively assess the potential efficacy of various treatment plans before intervention through virtually generated multi-timepoint imaging, providing a visual foundation for personalized treatment decisions. This research merges generative AI with dynamic risk models to achieve: 1) a transition from static assessment to dynamic simulation; 2) earlier survival predictions; and 3) personalized optimization of treatment plans. By eliminating dependence on longitudinal data, we aim to deliver more precise and individualized treatment decision support for advanced liver cancer patients, ultimately enhancing survival outcomes and quality of life.', 'detailedDescription': 'The entry point of this study is the proposition of ""generative longitudinal prediction,"" which utilizes only pre-treatment imaging to create high-fidelity predictions of post-treatment imaging. This approach effectively overcomes the clinical challenge of acquiring genuine longitudinal follow-up data. This paradigm shift not only tackles the scarcity of longitudinal data but also introduces an innovative method for treatment simulation using digital twins. Clinicians can intuitively assess the potential efficacy of various treatment plans before intervention through virtually generated multi-timepoint imaging, providing a visual foundation for personalized treatment decisions. This research merges generative AI with dynamic risk models to achieve: 1) a transition from static assessment to dynamic simulation; 2) earlier survival predictions; and 3) personalized optimization of treatment plans. By eliminating dependence on longitudinal data, we aim to deliver more precise and individualized treatment decision support for advanced liver cancer patients, ultimately enhancing survival outcomes and quality of life. The model was developed in a retrospective cohort, with validation and testing conducted in multiple retrospective and prospective cohorts, respectively.'}, 'conditionsModule': {'conditions': ['Transcatheter Arterial Chemoembolization', 'Unresectable Hepatocellular Carcinoma'], 'keywords': ['hepatocellular carcinoma', 'gengerative model', 'transcatheter arterial chemoembolization', 'immunotherapy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '18 Months', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 550, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'development cohort, validation cohort, test cohort', 'interventionNames': ['Other: Generative model']}], 'interventions': [{'type': 'OTHER', 'name': 'Generative model', 'description': 'Prospectively enroll pretreatment imaging data from patients with unresectable hepatocellular carcinoma undergoing TACE in combination with immunotherapy plus targeted therapy. Utilize a generative model to create virtual images that represent optimal treatment responses, and compare these virtual images with actual treatment response images collected during follow-up to evaluate the reliability of the generative model.', 'armGroupLabels': ['development cohort, validation cohort, test cohort']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall survival', 'description': 'defined as the time from the initial of combined therapy to death from any cause', 'timeFrame': 'Through study completion, an average of 20 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosed as unresectable hepatocellular carcinoma (HCC) by histopathology and/or clinical diagnosis (typical imaging features, clinical manifestations, laboratory tests, etc.) (Reference: Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition));\n* Patients with unresectable HCC receiving TACE combined with targeted immunotherapy;\n* Liver function classified as Child-Pugh A or B;\n* Aged 18 or above, regardless of gender;\n* Expected survival time 3 months;\n* ECOG PS score 2;\n* Meeting the following laboratory parameters: a) Hematologic function: Absolute neutrophil count 1.010/L; Platelet count 5010/L; Hemoglobin 90 g/L; International normalized ratio (INR) \\<1.7 or prothrombin time prolongation 4 seconds; b) Liver function: ALT/AST 5 upper limit of normal (ULN); Total bilirubin 210 mol/L \\[2.38 mg/dL\\]; Albumin 28 g/L; c) Renal function: Serum creatinine 1.5 ULN.\n\nExclusion Criteria:\n\n* Concurrent presence of other malignant tumors besides HCC;\n* Moderate to severe ascites (ascites scoring 3 points on the Child-Pugh scale); - - Receipt of other first-line, second-line, or third-line systemic therapies (including any regimen of systemic treatment) or any local therapies (including transcatheter interventional therapy, ablation therapy, internal/external radiotherapy, etc.), as well as surgical resection or herbal medicine within 4 weeks prior to TACE combined with targeted immunotherapy;\n* Incomplete data, such as missing baseline laboratory test results, unavailable or poor-quality imaging data, or lack of prognostic information;\n* Severe liver dysfunction: e.g., decompensated cirrhosis or other liver diseases significantly affecting bilirubin levels;\n* Severe comorbidities: e.g., refractory hypertension (blood pressure remaining above 150/100 mm Hg despite optimal medication), persistent arrhythmia (CTCAE grade 2 or higher), atrial fibrillation of any degree, prolonged QTc interval (\\>450 ms in males or \\>470 ms in females), renal insufficiency, etc.;\n* Co-infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS);\n* Pregnant or breastfeeding women;\n* Acute or chronic psychiatric disorders (including those affecting participant enrollment, treatment intervention, or follow-up).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Unresectable hepatocellular carcinoma undergoing TACE in combination with immunotherapy plus targeted therapy', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Zhongda hospital', 'city': 'Changzhou', 'state': 'Jiangsu', 'zip': '213003', 'country': 'China', 'geoPoint': {'lat': 31.77359, 'lon': 119.95401}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}",,"{'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2025-05-01', 'uploadDate': '2025-07-01T06:28', 'filename': 'Prot_000.pdf', 'size': 284710}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}}",False
"{'identificationModule': {'nctId': 'NCT00200486', 'orgStudyIdInfo': {'id': '02-05-127E'}, 'secondaryIdInfos': [{'id': 'NIH-R21-CA104402'}, {'id': '6R21DE023941-03', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/6R21DE023941-03'}, {'id': '3P50DE019032-14S2', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/3P50DE019032-14S2'}, {'id': '3U54CA274321-02S1', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/3U54CA274321-02S1'}], 'organization': {'fullName': 'Montefiore Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Molecular and Genomic Profiling of Head and Neck Tumors', 'officialTitle': 'Molecular and Genomic Profiling of Head and Neck Tumors to Explore Biomarkers Associated With Prognosis and Response to Therapy'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2002-10-01'}, 'primaryCompletionDateStruct': {'date': '2030-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2030-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2005-09-12', 'studyFirstSubmitQcDate': '2005-09-16', 'studyFirstPostDateStruct': {'date': '2005-09-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-02-27', 'lastUpdatePostDateStruct': {'date': '2025-03-04', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Montefiore Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}, {'name': 'National Institute of Dental and Craniofacial Research (NIDCR)', 'class': 'NIH'}, {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to study the genetic profile of head and neck tumors and their relationship to treatment response and outcome', 'detailedDescription': 'Previous research by our group using genetic microarray analysis of HNSCC and normal keratinocytes has identified two distinct groups of genetic expression based on clustering patterns of a subgroup of genes. Clinical data was summarized for each group and overall, patient segregation by gene expression profiling was a better predictor of outcome than clinicopathological variables. Further analysis identified 375 genes that discriminate between the genotypic subtypes of HNSCC. Overall, our preliminary data has shown that the pattern of global gene expression in a HNSCC specimen can be used as a predictor of prognosis. We isolated subsets of genes showing the greatest patterns of divergence in gene expression. We have also identified 366 over-expressed and 246 underexpressed genes when comparing primary tumor to normal surgical margins and have identified a similar number of genes whose expression has changed when comparing primary tumor to lymph node metastasis. Combining these data sets we have identified genes which consistently increase or decrease expression during progression from normal tissue to primary tumor, and subsequently to metastatic node. We have selected several candidate genes for subsequent analysis using HNSCC tissue arrays. Through DNA microarray analysis and other techniques for looking at genetic and molecular characteristics, a more detailed knowledge of the malignant transformation process, and alterations with therapy, in these patients may be obtained. This study will seek to perform comprehensive molecular and genetic profiling to improve biomarker development in HNSCC and correlate this data with patient clinical data. Ultimately it is hoped that tumor specific genetic abnormalities may be identified which could provide targets for treatment strategies such as gene therapy, immunotherapy, or other interventions.\n\nStudy Objectives:\n\nTo evaluate gene expression patterns in human head and neck squamous cell carcinoma and correlate this with treatment response, both surgical and non-surgical.\n\nTo identify a series of diagnostic markers in blood, urine and/or sputum for head and neck squamous cell carcinoma and study the mechanism of action of these proteins.'}, 'conditionsModule': {'conditions': ['Head and Neck Neoplasms'], 'keywords': ['genetic microarray', 'head and neck cancer']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': '1. Tumor specimens along with normal mucosa obtained at the time of surgery for biopsy or resection of primary or recurrent tumors of the head and neck\n2. blood, urine and sputum from patients participating in the tumor collection described above'}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'correlation of treatment response and prognosis (time to recurrence and survival) with genetic expression profile', 'timeFrame': '5 years'}], 'secondaryOutcomes': [{'measure': 'identify a series of diagnostic markers for head and neck tumors and study the mechanism of action of these proteins', 'timeFrame': 'variable'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* actual or suspected malignant or non-malignant tumors of the head and neck\n* planned biopsy and/or resection, or availability of paraffin embedded or stored frozen tumor tissue for non-genetic analysis\n\nExclusion Criteria:\n\n* insufficient tissue available for both standard diagnostic evaluation and study specimen', 'healthyVolunteers': False, 'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients with tumors of the head and neck who ar ehaving diagnostic biopsy or surgical resection of primary lesions or recurrences', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Stelby Augustine, RN', 'role': 'CONTACT', 'phone': '718-920-7054', 'email': 'staugust@montefiore.org'}, {'name': 'Richard V Smith, MD', 'role': 'CONTACT', 'phone': '718-920-2991', 'email': 'rsmith@montefiore.org'}], 'overallOfficials': [{'name': 'Richard V Smith, MD', 'affiliation': 'Montefiore Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Stelby Augustine', 'status': 'RECRUITING', 'city': 'The Bronx', 'state': 'New York', 'zip': '10467', 'country': 'United States', 'contacts': [{'name': 'Stelby Augustine, RN', 'role': 'CONTACT', 'phone': '718-920-7054', 'email': 'staugust@montefiore.org'}, {'name': 'Richard V Smith, MD', 'role': 'CONTACT', 'phone': '718-920-2991', 'email': 'rsmith@montefore.org'}, {'name': 'Richard V Smith, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Thomas Belbin, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Michael Prystowsky, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Schiff Bradley, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Cohen Perry, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Mehta Vikas, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Nicolas F Schlecht, PhD, MSC', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Geoffrey Childs, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Madhur K Garg, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Missak Haigentz, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Gregory Rosenblatt, PhD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}]}, 'referencesModule': {'references': [{'pmid': '37493178', 'type': 'RESULT', 'citation': 'Stone A, Liu J, Lin J, Schiff BA, Ow TJ, Mehta V, Smith RV. Value of Adherence to Posttreatment Follow-Up Guidelines for Head and Neck Squamous Cell Carcinoma. Laryngoscope. 2024 Feb;134(2):708-716. doi: 10.1002/lary.30909. Epub 2023 Jul 26.'}, {'pmid': '37046664', 'type': 'RESULT', 'citation': 'Shrivastava N, Chavez CG, Li D, Mehta V, Thomas C, Fulcher CD, Kawachi N, Bottalico DM, Prystowsky MB, Basu I, Guha C, Ow TJ. CDK4/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma. Cancers (Basel). 2023 Mar 28;15(7):2005. doi: 10.3390/cancers15072005.'}, {'pmid': '36477880', 'type': 'RESULT', 'citation': 'Li D, Thomas C, Shrivastava N, Gersten A, Gadsden N, Schlecht N, Kawachi N, Schiff BA, Smith RV, Rosenblatt G, Augustine S, Gavathiotis E, Burk R, Prystowsky MB, Guha C, Mehta V, Ow TJ. Establishment of a diverse head and neck squamous cancer cell bank using conditional reprogramming culture methods. J Med Virol. 2023 Feb;95(2):e28388. doi: 10.1002/jmv.28388.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006258', 'term': 'Head and Neck Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}]}}",False
"{'identificationModule': {'nctId': 'NCT07172386', 'orgStudyIdInfo': {'id': 'SETAR'}, 'organization': {'fullName': 'Tianjin Medical University Second Hospital', 'class': 'OTHER'}, 'briefTitle': 'Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC', 'officialTitle': 'A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma'}, 'statusModule': {'statusVerifiedDate': '2025-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-07-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-07-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-07-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-09-08', 'studyFirstSubmitQcDate': '2025-09-08', 'studyFirstPostDateStruct': {'date': '2025-09-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-13', 'lastUpdatePostDateStruct': {'date': '2025-09-16', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Tianjin Medical University Second Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': ""This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery"", 'detailedDescription': ""This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery, The main objective of the study was to evaluate whether the treatment was beneficial to patients undergoing surgery.""}, 'conditionsModule': {'conditions': ['Renal Cell Carcinoma (RCC)'], 'keywords': ['Toripalimab', 'Axitinib', 'Super-selective renal artery embolization', 'Advanced Renal Cell Carcinoma']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Embolization plus toripalimab and axitinib', 'type': 'EXPERIMENTAL', 'description': 'Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery', 'interventionNames': ['Drug: Toripalimab and axitinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Toripalimab and axitinib', 'description': ""Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles before surgery, and followed by 17 cycles' toripalimab for adjuvant therapy."", 'armGroupLabels': ['Embolization plus toripalimab and axitinib'], 'otherNames': ['Super-selective tumor arterial embolization']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'R0 Resection Rate', 'description': 'The proportion of patients who achieve complete resection with no residual tumor cells detected at the surgical margin, serving as a primary outcome measure to assess the success of surgical intervention in the study.', 'timeFrame': 'through study completion, an average of 3 year'}, {'measure': 'ORR', 'description': 'According to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, the objective response rate (ORR) following preoperative treatment was assessed by the investigator.', 'timeFrame': 'through study completion, an average of 3 year'}, {'measure': 'Preoperative Treatment Safety: Treatment-Related Side Effects', 'description': 'Treatment-Related Side Effects', 'timeFrame': 'Through treatment completion (before surgery), an average of 4 cycles (each cycle is 21 days)'}], 'secondaryOutcomes': [{'measure': 'Perioperative Complications', 'description': 'Intraoperative Blood Loss, Karnofsky Score, and Hospital Stay', 'timeFrame': 'Throughout treatment until 30 days after surgery'}, {'measure': 'Progression free survival', 'description': 'Progression free survival was assessed by imaging (enhanced CT, enhanced MRI or both ) after surgery every 12 weeks until 12 months.', 'timeFrame': 'Every 12 weeks until 12 months after surgery'}, {'measure': 'Major Pathological Response', 'description': 'Defined as 10% residual viable tumor cells in the resected tumor specimen (assessed by pathological examination after surgery). Serves as a secondary outcome to evaluate the effectiveness of preoperative therapy in reducing tumor burden at the pathological level.', 'timeFrame': 'Within 14 days after surgical resection'}, {'measure': 'Patient-Reported Quality of Life', 'description': 'EORTC QLQ-C30 and FKSI-15 Scores', 'timeFrame': 'Through adjuvant treatment completion (after surgery), with assessments once every 3 weeks for a total of 17 cycles (each cycle is 21 days)'}, {'measure': 'Overall Survival (OS)', 'description': 'Subjects will undergo survival follow-up until the earliest occurrence of the following events: subject death, loss to follow-up, withdrawal of informed consent, completion of 5 years of survival follow-up, or study termination.', 'timeFrame': 'Follow-up is performed once every 3 months (14 days)'}], 'otherOutcomes': [{'measure': 'Rate of responser with predictive biomarker positive', 'description': 'Bulk RNA-seq and/or single cell RNA-seq were performed in part of tissues before and after neoadjuvant treatment to seek biomarkers predicting Response', 'timeFrame': 'Through treatment completion (before surgery), an average of 4 cycles (each cycle is 21 days)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Age  18 years\n* Patients with pathologically and radiographically confirmed renal cell carcinoma:\n\n  * cT2N0M0 with Grade 4 or sarcomatoid feature;\n  * cT3-4N0M0;\n  * cTanyN1M0;\n  * M1 that can be returned to M0 through local therapy\n* Preoperative imaging evaluation can be performed radical excision or tumor reduction surgery\n* There are no suspected brain metastases\n* The presence of measurable lesions was assessed according to RECISTv1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Organ function level must meet the following requirements: Hematological indexes: neutrophil count \\>= 1.5x10\\^9/L, platelet count \\>= 100x10\\^9/L, hemoglobin \\>= 9.0 g/dl (can be maintained by blood transfusion); Liver function: total bilirubin \\<=1.5 ULN, alanine aminotransferase and aspartate aminotransferase \\<=1.5 ULN\n* Non-surgically sterilized or reproductive-age female patients must use a medically approved contraceptive method (such as an intrauterine device, oral contraceptives, or condoms) during the study treatment period and for 3 months after its completion; Female patients who are not surgically sterilized or are of childbearing potential must have a negative serum or urine HCG test within 7 days prior to study enrollment and must not be lactating. Male patients who are not surgically sterilized or are of childbearing potential must agree to use one medically approved contraceptive method with their spouse during the study treatment period and for 3 months after the study treatment period ends.\n* The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up\n\nExclusion Criteria:\n\n* Prior receipt of radiotherapy, chemotherapy, long-term or high-dose corticosteroid therapy, surgery, or molecular targeted therapy\n* Subjects with a history of or concurrent other malignancies (except those controllable and not affecting 2-year survival)\n* Prior treatment with other PD-1/PD-L1 therapies; Known history of allergy to macromolecular protein preparations or any known PD-1 component\n* Active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or childhood asthma that has achieved complete remission without requiring any intervention in adulthood may be included; subjects requiring medical intervention with bronchodilators for asthma are excluded);\n* Subjects currently using immunosuppressive agents for immunosuppression purposes and continuing such use within 2 weeks prior to enrollment\n* Uncontrolled cardiac clinical symptoms or diseases, such as:\n\n  * New York Heart Association (NYHA) Class II or higher heart failure;\n  * Unstable angina;\n  * Myocardial infarction within the past year;\n  * Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention\n* Coagulation abnormalities (PT \\> 16s, APTT \\> 43s, TT \\> 21s, Fbg \\> 2g/L) with bleeding tendency or currently receiving thrombolytic or anticoagulant therapy;\n* Active gastrointestinal bleeding within 3 months prior to first dose due to esophageal varices, active gastric or duodenal ulcer, ulcerative colitis, portal hypertension, or unresected tumors; or other conditions judged by the investigator to potentially cause gastrointestinal bleeding or perforation\n* History or current presence of major bleeding (30 mL within 3 months), hemoptysis (5 mL fresh blood within 4 weeks), or thromboembolic events (including stroke and/or transient ischemic attack) within 12 months\n* Active infection or unexplained fever \\>38.5C occurring during screening or prior to first dose\n* History of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 4 weeks prior to first dose\n* Objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or severe pulmonary impairment\n* Subjects with congenital or acquired immunodeficiency, such as HIV infection, or active hepatitis (transaminase levels not meeting inclusion criteria; for hepatitis B: HBV DNA 10/ml; for hepatitis C: HCV RNA 10/ml); chronic hepatitis B virus carriers with HBV DNA 2000 IU/ml (10 copies/ml) must concurrently receive antiviral therapy during the study to be eligible for enrollment\n* Subjects currently participating in other clinical studies or those who completed a prior clinical study within the past month; subjects may receive other systemic antitumor therapies during the study period\n* Administration of live vaccines within 4 weeks prior to study drug initiation or during the study period\n* Known history of psychiatric drug abuse, alcoholism, or substance abuse;\n* Inability or refusal to bear out-of-pocket costs for examinations and treatments\n* The investigator deems the subject should be excluded from this study, such as when the investigator determines the subject has other factors that may necessitate premature termination of the study, including: other serious illnesses (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, or family/social factors that may compromise subject safety or interfere with data/sample collection.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Shimiao Zhu, MD,PhD', 'role': 'CONTACT', 'phone': '+86 88328607', 'email': 'zhushimiao@tmu.edu.cn'}], 'overallOfficials': [{'name': 'Changyi Quan, MD', 'affiliation': 'Tianjin Medical University Second Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Tianjin Medical University Second Hospital', 'status': 'RECRUITING', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300211', 'country': 'China', 'contacts': [{'name': 'Changyi Quan, PhD', 'role': 'CONTACT', 'phone': '13388067990', 'email': '345920147@qq.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}]}, 'referencesModule': {'references': [{'type': 'BACKGROUND', 'citation': 'ournal/SourcePresented at: American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO - GU) 2025  Publication Year2025  Other InfoAbstract #477684'}, {'pmid': '25536394', 'type': 'BACKGROUND', 'citation': 'Muller A, Rouviere O. Renal artery embolization-indications, technical approaches and outcomes. Nat Rev Nephrol. 2015 May;11(5):288-301. doi: 10.1038/nrneph.2014.231. Epub 2014 Dec 23.'}, {'pmid': '23947972', 'type': 'BACKGROUND', 'citation': 'Rothrock NE, Jensen SE, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, Cella D. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. Value Health. 2013 Jul-Aug;16(5):789-96. doi: 10.1016/j.jval.2013.04.015. Epub 2013 Jun 19.'}, {'pmid': '10109801', 'type': 'BACKGROUND', 'citation': 'EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9.'}, {'pmid': '33284113', 'type': 'BACKGROUND', 'citation': 'Powles T, Plimack ER, Soulieres D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.'}, {'pmid': '23964934', 'type': 'BACKGROUND', 'citation': 'Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.'}, {'pmid': '29562145', 'type': 'BACKGROUND', 'citation': 'Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.'}, {'pmid': '34159090', 'type': 'BACKGROUND', 'citation': 'Zhang Z, Xiong L, Wu Z, Liu H, Ning K, Peng Y, Yu C, Ding Y, Weng D, Xia J, Jiang L, Guo S, Han H, Zhou F, Dong P. Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. Transl Androl Urol. 2021 May;10(5):2091-2102. doi: 10.21037/tau-21-406.'}, {'pmid': '27663893', 'type': 'BACKGROUND', 'citation': ""Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016 Dec;6(12):1382-1399. doi: 10.1158/2159-8290.CD-16-0577. Epub 2016 Sep 23.""}, {'pmid': '34049847', 'type': 'BACKGROUND', 'citation': 'Gorin MA, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, Trock BJ, Pierorazio PM, Nirschl TR, Salles DC, Stein JE, Lotan TL, Taube JM, Drake CG, Allaf ME. Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. Eur Urol Oncol. 2022 Feb;5(1):113-117. doi: 10.1016/j.euo.2021.04.002. Epub 2021 May 26.'}, {'pmid': '21621907', 'type': 'BACKGROUND', 'citation': 'Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov;60(5):964-71. doi: 10.1016/j.eururo.2011.05.032. Epub 2011 May 25.'}, {'pmid': '27034725', 'type': 'BACKGROUND', 'citation': 'Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr;8(2):130-41. doi: 10.1177/1756287215612962. Epub 2015 Nov 20.'}, {'pmid': '28967554', 'type': 'BACKGROUND', 'citation': 'Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.'}, {'pmid': '30346481', 'type': 'BACKGROUND', 'citation': 'Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.'}, {'pmid': '28902533', 'type': 'BACKGROUND', 'citation': 'Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.'}, {'pmid': '26969090', 'type': 'BACKGROUND', 'citation': 'Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9.'}, {'pmid': '27718781', 'type': 'BACKGROUND', 'citation': 'Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.'}, {'pmid': '34407342', 'type': 'BACKGROUND', 'citation': 'Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.'}, {'pmid': '28213859', 'type': 'BACKGROUND', 'citation': 'Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Curr Urol Rep. 2017 Feb;18(2):15. doi: 10.1007/s11934-017-0661-3.'}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002292', 'term': 'Carcinoma, Renal Cell'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D007680', 'term': 'Kidney Neoplasms'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000656314', 'term': 'toripalimab'}, {'id': 'D000077784', 'term': 'Axitinib'}], 'ancestors': [{'id': 'D001549', 'term': 'Benzamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001565', 'term': 'Benzoates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D007191', 'term': 'Indazoles'}, {'id': 'D011720', 'term': 'Pyrazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}",False
"{'identificationModule': {'nctId': 'NCT07252986', 'orgStudyIdInfo': {'id': '2025-COMPASS-BC'}, 'secondaryIdInfos': [{'id': '2025-COMPASS-BC', 'type': 'OTHER', 'domain': 'The Second Affiliated Hospital, Zhejiang University School of Medicine'}], 'organization': {'fullName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'class': 'OTHER'}, 'briefTitle': 'Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence', 'officialTitle': 'A Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence and Its Clinical Translation Research', 'acronym': 'COMPASS-BC'}, 'statusModule': {'statusVerifiedDate': '2025-11', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2028-12-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-12-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-11-19', 'studyFirstSubmitQcDate': '2025-11-19', 'studyFirstPostDateStruct': {'date': '2025-11-28', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-19', 'lastUpdatePostDateStruct': {'date': '2025-11-28', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Jian Huang', 'investigatorTitle': 'Head of Breast Surgery Department', 'investigatorAffiliation': 'Second Affiliated Hospital, School of Medicine, Zhejiang University'}, 'leadSponsor': {'name': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Breast cancer is one of the most common malignancies in women worldwide, and distant metastasis is the main cause of poor prognosis and death. This project aims to construct a precision prediction system based on multi-omics (digital pathology, immunohistochemistry, proteomics, gene sequencing) and artificial intelligence to predict distant and organ-specific metastasis (bone, lung, liver, brain) in breast cancer, analyze its mechanisms, and provide new solutions for precision medicine.'}, 'conditionsModule': {'conditions': ['Breast', 'Breast Cancer', 'Pathology']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Based on the study protocol, the following specific types of biological samples will be collected, processed, and retained:\n\n* Primary tumor tissue\n* Metastatic tumor tissue, specifically from liver, lung, bone, and brain metastases\n* Paired samples of primary and metastatic tumors (with a goal of over 1,000 pairs)\n* Blood samples, which will be used for liquid biopsy\n* The informed consent form specifies the collection of 6-10ml of peripheral blood\n* Data from previously retained biological samples, such as plasma\n* Patient-derived breast organoids All collected samples will be stored at -80C.'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group 1', 'description': 'Metastatic Risk Stratification (High/Medium/Low Risk)'}, {'label': 'Group 2', 'description': 'Organ-Specific Metastasis (Bone/Lung/Liver/Brain)'}, {'label': 'Group 3', 'description': 'Non-Metastatic Control Group'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Metastasis-Free Survival', 'description': 'Time from initial breast cancer diagnosis to the occurrence of distant metastasis.', 'timeFrame': 'From diagnosis up to December 30, 2028'}], 'secondaryOutcomes': [{'measure': 'Performance of Prediction Models', 'description': 'Evaluate the performance of (1) the metastatic risk stratification model, (2) the organ-specific metastasis prediction model, and (3) the metastasis time-window prediction model.\n\nMeasure: Accuracy and Area Under the Curve (AUC). (Target accuracy 80%, AUC 0.80)', 'timeFrame': 'At the end of the study (December 2028)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Female patients pathologically diagnosed with breast cancer at our hospital or participating centers between January 1, 2000, and December 30, 2028.\n2. Must meet one of the following: 1) Initially diagnosed with breast cancer at our hospital, has developed distant metastasis (liver, bone, lung, or brain), and has a biopsy or surgical specimen from the metastatic site stored at our hospital, with complete clinical information available. 2) Primary tumor specimen is not at our hospital, but a biopsy or surgical specimen from a distant metastatic site (liver, bone, lung, brain) is stored at our hospital.\n\nExclusion Criteria:\n\n1. Concomitant metastatic malignancy from another primary cancer.\n2. Incomplete clinical information.', 'healthyVolunteers': False, 'sex': 'FEMALE', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The study population comprises female patients diagnosed with breast cancer between 2000 and 2028, identified through participating hospital centers. This includes patients who have developed distant (organ-specific) metastasis (liver, lung, bone, or brain) and for whom primary and/or metastatic tissue samples are available.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Fengbo Huang, MD', 'role': 'CONTACT', 'phone': '0571-87783914', 'email': 'keyanlunli_zheer@163.com'}], 'locations': [{'facility': 'The Second Affiliated Hospital, Zhejiang University School of Medicine', 'city': 'Hangzhou', 'state': 'Zhejiang', 'zip': '310000', 'country': 'China', 'contacts': [{'name': 'Fengbo Huang, MD', 'role': 'CONTACT', 'phone': '0571-87783914', 'email': 'keyanlunli_zheer@163.com'}, {'name': 'Jian Huang, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Sharing of IPD is not guaranteed and is strictly conditional. First, consent for the long-term storage and future research use of data is collected as a separate, optional item on the Informed Consent Form. Therefore, IPD cannot be shared from any participant who does not provide this specific optional consent.\n\nSecond, the study involves highly sensitive multi-modal data, including digital pathology, proteomics, and genomic sequencing. This data is subject to strict privacy-preserving protocols (such as encryption and differential privacy) and oversight by the institutional data security committee to protect participant confidentiality and prevent re-identification.'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}",False
"{'identificationModule': {'nctId': 'NCT04878783', 'orgStudyIdInfo': {'id': 'URomLS2022'}, 'organization': {'fullName': 'University of Roma La Sapienza', 'class': 'OTHER'}, 'briefTitle': 'Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG', 'officialTitle': 'CT Scan-Based Radiomics and Molecular Expression Predictive Model to Assess Tumor Regression Grade Following Perioperative Chemotherapy in Esophago-Gastric Junction and Gastric Cancer'}, 'statusModule': {'statusVerifiedDate': '2024-05', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-12-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-10-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-10-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-05-06', 'studyFirstSubmitQcDate': '2021-05-06', 'studyFirstPostDateStruct': {'date': '2021-05-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-08', 'lastUpdatePostDateStruct': {'date': '2024-05-09', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Giovanni Maria Garbarino', 'investigatorTitle': 'M.D.', 'investigatorAffiliation': 'University of Roma La Sapienza'}, 'leadSponsor': {'name': 'University of Roma La Sapienza', 'class': 'OTHER'}, 'collaborators': [{'name': 'Andrea Laghi', 'class': 'UNKNOWN'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy. The molecular expression of the neoplasms will be evaluated to assess its association with the TRG and the radiomic features.', 'detailedDescription': ' To compare the radiomic features of the CT scans at the time of diagnosis (T0) and at the end of the preoperative chemotherapy (T1) in order to predict the TRG with the texture analysis on the first CT scan.\n\nA non-good response (non-GR) has shown to be predictable with texture analysis on the pre-treatment CT scan.\n\nTherefore, we hypothesize that texture analysis could let to identify the good response patients.\n\n To find correlation between the molecular expression of the tumor and the radiomics features.\n\nTexture analysis on the pre-chemotherapy CT scan founded that entropy and compactness were higher and uniformity lower in responders. Nonetheless the association between radiomics features and molecular expression has not been investigated yet.\n\nTherefore, we hypothesize to add some others radiomics signatures to the analysis and to find an association with the molecular expression.\n\n To find correlation between the molecular expression of the tumor and the TRG.\n\nMSI gastric cancer has been shown to be less responsive to preoperative chemotherapy.\n\nTherefore, we hypothesize to confirm this result.'}, 'conditionsModule': {'conditions': ['Gastric Cancer', 'Adenocarcinoma of the Stomach'], 'keywords': ['radiomics', 'molecular expression', 'perioperative chemotherapy', 'FLOT', 'gastric cancer', 'esophago-gastric junction cancer']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Gastrectomy or esophagogastrectomy specimen'}, 'enrollmentInfo': {'count': 138, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'CT scan', 'description': 'Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study', 'otherNames': ['FLOT chemotherapy', 'Radical Gastrectomy with D2 Lymphadenectomy', 'Radical Esophagogastrectomy with D2 Lymphadenectomy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Predictive performance of radiomics analysis on the pre-treatment CT scan.', 'description': 'Comparing the radiomic features of the CT scans at the time of diagnosis (T0) and at the end of the preoperative chemotherapy (T1) in order to predict the TRG with the texture analysis on the first CT scan.', 'timeFrame': '2 months'}], 'secondaryOutcomes': [{'measure': 'Association of the radiomics features with the molecular expression of the tumor.', 'description': 'Texture analysis on the pre-chemotherapy CT scan founded that entropy and compactness were higher and uniformity lower in responders. Nonetheless the association between radiomics features and molecular expression has not been investigated yet.\n\nTherefore, we hypothesize to add some others radiomics signatures to the analysis and to find an association with the molecular expression.', 'timeFrame': '2 months'}, {'measure': 'Evaluation of the association between TRG and the molecular expression of the tumor.', 'description': 'Investigate if the molecular expression of the tumor can influence the TRG', 'timeFrame': '2 months'}, {'measure': 'Association between radiomics and molecular expression in regards to long-term outcomes', 'description': 'Analysis of the 3 and 5y DFS and OS of patients with the radiomics and molecular expression profile', 'timeFrame': '5 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with histologically proven adenocarcinoma of the EGJ (Siewert II-III) or stomach.\n* Preoperative staging: cT2-T4a, cN0-N3, M0.\n* Patients \\>18 years old.\n* Patients undergoing perioperative chemotherapy with Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT).\n\nExclusion Criteria:\n\n* Siewert I EGJ tumor\n* Patients undergoing preoperative radiotherapy.\n* Absence of both pre and post-chemotherapy CT-scan.\n* Patients with tumor progression during preoperative chemotherapy.\n* Patients undergoing other neoadjuvant chemotherapy regimen different from FLOT\n* Exploratory laparoscopy with positive cytology on the peritoneal lavage or evidence of peritoneal carcinosis', 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients with cT2-T4a, cN0-N3, M0 gastric or EGJ cancer who undergo FLOT perioperative chemotherapy followed by radical surgical resection.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'University of Padova', 'city': 'Padua', 'zip': '35128', 'country': 'Italy', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'facility': 'Link Campus University', 'city': 'Roma', 'zip': '00165', 'country': 'Italy', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'facility': 'Giovanni Maria Garbarino', 'city': 'Roma', 'zip': '00189', 'country': 'Italy', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'facility': 'University of Verona', 'city': 'Verona', 'country': 'Italy', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'facility': 'Amsterdam UMC location University of Amsterdam', 'city': 'Amsterdam', 'state': 'North Holland', 'zip': '1081 HV', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013274', 'term': 'Stomach Neoplasms'}], 'ancestors': [{'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D014057', 'term': 'Tomography, X-Ray Computed'}], 'ancestors': [{'id': 'D007090', 'term': 'Image Interpretation, Computer-Assisted'}, {'id': 'D003952', 'term': 'Diagnostic Imaging'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D011856', 'term': 'Radiographic Image Enhancement'}, {'id': 'D007089', 'term': 'Image Enhancement'}, {'id': 'D010781', 'term': 'Photography'}, {'id': 'D011859', 'term': 'Radiography'}, {'id': 'D014056', 'term': 'Tomography, X-Ray'}, {'id': 'D014054', 'term': 'Tomography'}]}}",False
"{'identificationModule': {'nctId': 'NCT04291105', 'orgStudyIdInfo': {'id': 'VYR-VSV2-203'}, 'organization': {'fullName': 'Vyriad, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients', 'officialTitle': 'Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-04-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-02-25', 'studyFirstSubmitQcDate': '2020-02-28', 'studyFirstPostDateStruct': {'date': '2020-03-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-25', 'lastUpdatePostDateStruct': {'date': '2025-03-26', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Vyriad, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Regeneron Pharmaceuticals', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.', 'detailedDescription': ""Patients enrolled into three parallel doublet cohorts with an optimal Simon's two stage design. Patients will receive Voyager V1 as a direct to tumor injection (IT) in all 3 cancer groups and cemiplimab via IV infusion. Patients will return for treatment every 3 weeks until lack of clinical benefit or limiting toxicity. Efficacy evaluations will be conducted every 6 weeks.""}, 'conditionsModule': {'conditions': ['Melanoma', 'Head and Neck Squamous Cell Carcinoma', 'Colo-rectal Cancer'], 'keywords': ['Solid Tumor']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 87, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Melanoma intratumoral', 'type': 'EXPERIMENTAL', 'description': 'Melanoma, IT VV1 + IV cemiplimab Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.', 'interventionNames': ['Biological: VV1', 'Biological: Cemiplimab']}, {'label': 'Head and Neck SCC intratumoral', 'type': 'EXPERIMENTAL', 'description': 'HNSCC, IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.', 'interventionNames': ['Biological: VV1', 'Biological: Cemiplimab']}, {'label': 'Colo-rectal Carcinoma intratumoral (Arm closed)', 'type': 'EXPERIMENTAL', 'description': '(CLOSED) IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.', 'interventionNames': ['Biological: VV1', 'Biological: Cemiplimab']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'VV1', 'description': 'VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit', 'armGroupLabels': ['Colo-rectal Carcinoma intratumoral (Arm closed)', 'Head and Neck SCC intratumoral', 'Melanoma intratumoral'], 'otherNames': ['VSV-IFN-NIS, Voyager V1, VV1']}, {'type': 'BIOLOGICAL', 'name': 'Cemiplimab', 'description': 'Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.', 'armGroupLabels': ['Colo-rectal Carcinoma intratumoral (Arm closed)', 'Head and Neck SCC intratumoral', 'Melanoma intratumoral'], 'otherNames': ['Libtayo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective response rate (ORR) per imaging assessment', 'description': 'Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1', 'timeFrame': 'within 24 months'}], 'secondaryOutcomes': [{'measure': 'Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0', 'description': 'Safety and tolerability', 'timeFrame': 'within 24 months'}, {'measure': 'Serum concentration time', 'description': 'Serum concentration time data using RT-PCR of VSV-IFN-NIS and systemic cemiplimab levels', 'timeFrame': 'within 24 months'}, {'measure': 'To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFN', 'description': 'To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFN expression', 'timeFrame': 'within 24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion:\n\n1. Age 18 years on day of signing informed consent.\n2. Specific by tumor cohorts:\n\n   a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic HSNCC suitable for first line immunotherapy.\n\n   i. HPV+ and HPV- patients are allowed.\n\n   ii. Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology) or salivary gland tumors.\n\n   iii. PD-L1 status  1% per local CPS score. Samples should be provided to central lab for post-hoc centralized testing.\n\n   iv. At least 12 months between last dose of prior adjuvant therapy and date of relapse diagnosis (if given). For the purposes of this protocol, ""prior adjuvant therapy"" only applies to full dose systemic chemotherapy (such as pre-operative systemic induction chemotherapy), but does not include radiation + surgery, or radiation + low or partial dose platinum radiosensitization. There is no time limit (washout) between the end of any prior radiation/ chemoradiation and the start of study drug v. No prior anti-PD-(L)1 treatment for HNSCC.\n\n   b. For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or metastatic cutaneous melanoma for which no existing options are considered to provide clinical benefit.\n\n   i. Best response of uPR, SD or PD to an anti-PD-(L)1-containing regimen.\n\n   ii. Prior anti-PD-(L)1 therapy must have lasted  12 weeks.\n\n   iii. Radiological progression was demonstrated during or after therapy with a PD-(L)1 immune CPI (only one prior line of PD-(L)1 therapy is permitted.\n\n   iv. If patient received anti-PD-1 as prior adjuvant therapy, patient should have relapsed during therapy or within the subsequent 6 months after last dose. Note: Progression on ipilimumab is not required.\n\n   v. Patients with BRAF V600-positive tumor(s) should have received prior treatment with a BRAF inhibitor (alone or in combination with a MEK inhibitor) in addition to treatment with an anti-PD-1 or to have declined targeted therapy. Note: Patients with BRAF V600-positive tumors with no clinically significant tumor-related symptoms nor evidence of rapidly progressive disease are not required to be treated with a BRAF inhibitor (alone or in combination with a MEK inhibitor) based on investigator\'s decision\n\n   c. For the CRC cohort, a histologically confirmed diagnosis of advanced and/or metastatic CRC.\n\n   i. Received or are not eligible for standard of care fluoropyrimidine(s), oxaliplatin, irinotecan, anti-VEGF and EGFR-targeted therapies.\n\n   ii. Non-microsatellite instability high (non-MSI high).\n\n   iii. Progression on previous systemic therapy.\n3. At least one tumor lesion amenable to IT injection and biopsy that has not been previously irradiated.\n4. Measurable disease based on RECIST 1.1., including  1 measurable lesion(s) to be injected\n5. Performance status of 0 or 1 on the ECOG Performance Scale\n6. Life expectancy of \\>3 months.\n7. Willingness to provide biological samples required for the duration of the study, including a fresh tumor biopsy sample whilst on study.\n8. Adequate organ function assessed by laboratory values obtained 14 days prior to enrollment\n\nExclusion:\n\nPatients meeting any of the following exclusion criteria at screening/Day -1 of first dosing will not be enrolled in the study:\n\n1. Availability of and patient acceptance of an alternative curative therapeutic option.\n2. Patients with tumor lesion(s) \\> 5cm in diameter.\n3. Recent or ongoing serious infection, including any active Grade 3 or higher per the NCI CTCAE, v5.0 viral, bacterial, or fungal infection within 2 weeks of registration.\n4. Patients who have a diagnosis of ocular, mucosal or acral melanoma.\n5. Known seropositivity for and with active infection with HIV.\n6. Seropositive for and with evidence of active viral infection with HBV.\n7. Seropositive for and with active viral infection with HCV.\n8. Known history of active or latent TB.\n9. Any concomitant serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months).\n10. Prior therapy within the following timeframe before the planned start of study treatment as follows:\n\n    1. Small molecule inhibitors, and/or other investigational agent:  2 weeks or 5 half-lives, whichever is shorter.\n    2. Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies:  3 weeks or 5 half-lives, whichever is shorter.\n    3. Radioimmunoconjugates or other similar experimental therapies  6 weeks or 5 half-lives, whichever is shorter.\n11. NYHA classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT).\n12. Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment\n13. Immunodeficiency or immunosuppression, including systemic corticosteroids at \\>10 mg/day prednisone or equivalent within 1 week prior to planned start of study treatment.\n14. History of Grade 3 or 4 immune-mediated adverse reaction to immune CPIs.\n15. Toxicities from previous therapies that have not resolved to a Grade 1 or less.\n16. History of non-infectious pneumonitis that required steroids, or current pneumonitis.\n17. High volume disease, as assessed clinically by the medical monitor via parameters such as radiologic impression and tumor markers or lactate dehydrogenase (LDH).\n18. Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.\n\n18.19. Known concurrent malignancy.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jennifer boughton', 'role': 'CONTACT', 'phone': '9085533135', 'email': 'Jboughton@vyriad.com'}], 'overallOfficials': [{'name': 'Alice Bexon, MD', 'affiliation': 'CMO', 'role': 'STUDY_CHAIR'}, {'name': 'Stephen J Russell, MD, Ph.D.', 'affiliation': 'Clinical Lead', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Mayo Clinical', 'status': 'WITHDRAWN', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85054', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'City of Hope Medical Center', 'status': 'WITHDRAWN', 'city': 'Durate', 'state': 'California', 'zip': '91010', 'country': 'United States'}, {'facility': 'USC Norris Comprehensive Cancer Center', 'status': 'WITHDRAWN', 'city': 'Los Angeles', 'state': 'California', 'zip': '90033', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'HOAG Memorial Hospital Presbyterian', 'status': 'WITHDRAWN', 'city': 'Newport Beach', 'state': 'California', 'zip': '92663', 'country': 'United States', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'facility': ""Saint John's Health Center - John Wayne Cancer Institute (JWCI)"", 'status': 'TERMINATED', 'city': 'Santa Monica', 'state': 'California', 'zip': '90404', 'country': 'United States', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'facility': 'Stanford Health Care', 'status': 'WITHDRAWN', 'city': 'Stanford', 'state': 'California', 'zip': '94305', 'country': 'United States', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'facility': 'Yale University', 'status': 'RECRUITING', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520-8032', 'country': 'United States', 'contacts': [{'name': 'Neta Shanwetter Levit, MPH', 'role': 'CONTACT', 'phone': '203.500.0834', 'email': 'Neta.shanwetterlevit@yale.edu'}, {'name': 'Barbara Johnson', 'role': 'CONTACT', 'email': 'barbara.johnson@yale.edu'}, {'name': 'Mario Sznol, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'Georgetown University Medical Center', 'status': 'WITHDRAWN', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'zip': '20007', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'Mayo Clinical', 'status': 'WITHDRAWN', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'University of Miami', 'status': 'COMPLETED', 'city': 'Miami', 'state': 'Florida', 'zip': '33136', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Ochsner Clinic Foundation', 'status': 'RECRUITING', 'city': 'New Orleans', 'state': 'Louisiana', 'zip': '70121', 'country': 'United States', 'contacts': [{'name': 'Amanda Woolery, RN, BSN', 'role': 'CONTACT', 'phone': '504-842-0275.', 'email': 'amanda.woolery@ochsner.org'}, {'name': 'Daniel Johnson, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'facility': 'Massachusetts General Hospital Cancer Center', 'status': 'WITHDRAWN', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Masonic Cancer Center, University of Minnesota', 'status': 'WITHDRAWN', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55455', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'facility': 'Mayo Clinic', 'status': 'RECRUITING', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'contacts': [{'name': 'Clinical Trials Referal Office', 'role': 'CONTACT', 'phone': '855-776-0015'}, {'name': 'Patrick McGarrah, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'facility': 'Billings Clinic Montana Cancer Consortium', 'status': 'TERMINATED', 'city': 'Billings', 'state': 'Montana', 'zip': '59101', 'country': 'United States', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'facility': 'Atlantic Health', 'status': 'WITHDRAWN', 'city': 'Morristown', 'state': 'New Jersey', 'zip': '07960', 'country': 'United States', 'geoPoint': {'lat': 40.79677, 'lon': -74.48154}}, {'facility': 'Rutgers Cancer Institute of New Jersey', 'status': 'WITHDRAWN', 'city': 'New Brunswick', 'state': 'New Jersey', 'zip': '08901', 'country': 'United States', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'facility': 'Icahn School of Medicine at Mount Sinai', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10029', 'country': 'United States', 'contacts': [{'name': 'Ashley Poliak Hammad, MSN', 'role': 'CONTACT', 'phone': '212-824-7309', 'email': 'Ashley.hammad@mssm.edu'}, {'name': 'Thomas Marron, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'University of Cincinnati Medical Center', 'status': 'RECRUITING', 'city': 'Cincinnati', 'state': 'Ohio', 'zip': '45219', 'country': 'United States', 'contacts': [{'name': 'Trisha Wise-Draper, MD, PhD', 'role': 'CONTACT', 'phone': '513-584-7698', 'email': 'cancer@uchealth.com'}], 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'facility': 'Ohio State University', 'status': 'WITHDRAWN', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43210', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'UPMC', 'status': 'WITHDRAWN', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15213', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Sanford Cancer Center', 'status': 'RECRUITING', 'city': 'Sioux Falls', 'state': 'South Dakota', 'zip': '57104', 'country': 'United States', 'contacts': [{'name': 'Staci Vogel', 'role': 'CONTACT', 'phone': '605-312-3320', 'email': 'staci.vogel@sanfordhealth.org'}, {'name': 'Steven Powell, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'facility': 'UT Health San Antonio MD Anderson Cancer Center', 'status': 'WITHDRAWN', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Hospital Sao Rafael', 'status': 'RECRUITING', 'city': 'Salvador', 'state': 'BR', 'zip': '41253-190', 'country': 'Brazil', 'contacts': [{'name': 'Fernanda Coelho', 'role': 'CONTACT'}, {'name': 'Rodrigo Guedes, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': -12.97563, 'lon': -38.49096}}, {'facility': 'INCA', 'status': 'RECRUITING', 'city': 'Rio de Janeiro', 'state': 'Rio de Janeiro', 'zip': '20231-050', 'country': 'Brazil', 'contacts': [{'name': 'Alexssandra Lima, MD', 'role': 'CONTACT', 'phone': '55 21 3207-2988', 'email': 'Falves@inca.gov.br'}], 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'facility': 'Hospital Moinhos de Vento', 'status': 'RECRUITING', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'zip': '90035-000', 'country': 'Brazil', 'contacts': [{'name': 'Fabio Franke, MD', 'role': 'CONTACT', 'phone': '51-33142965'}, {'name': 'Desiree Deconte', 'role': 'CONTACT', 'email': 'desiree.deconte@hmv.org.br'}], 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'facility': 'Hospital de Amor de Barretos', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Barretos', 'state': 'So Paulo', 'zip': '14.784-400', 'country': 'Brazil', 'geoPoint': {'lat': -20.55722, 'lon': -48.56778}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}, {'id': 'D000077195', 'term': 'Squamous Cell Carcinoma of Head and Neck'}, {'id': 'D003110', 'term': 'Colonic Neoplasms'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000627974', 'term': 'cemiplimab'}]}}",False
"{'identificationModule': {'nctId': 'NCT03751566', 'orgStudyIdInfo': {'id': 'MOU-001'}, 'organization': {'fullName': 'Masaryk Memorial Cancer Institute', 'class': 'OTHER'}, 'briefTitle': 'Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors', 'officialTitle': 'Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors'}, 'statusModule': {'statusVerifiedDate': '2025-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-10-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-04', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2026-10-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-11-15', 'studyFirstSubmitQcDate': '2018-11-21', 'studyFirstPostDateStruct': {'date': '2018-11-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-09-23', 'lastUpdatePostDateStruct': {'date': '2025-09-25', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Masaryk Memorial Cancer Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The aim of the study is to evaluate the benefit of the acupuncture as healing modalities in the therapy of acute toxicity of radiotherapy.', 'detailedDescription': 'The study will enroll 100 patients in current radiotherapy of the head and neck cancer with acute radiotoxic symptoms at least of G1. The patients will be randomized (by ticket) in two regimens 1:1.\n\nRegimen A (control regimen): standard support treatment of adverse events of the radiotherapy.\n\nRegimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.\n\nDue to the disease and patients differences, treatment will be individualized. Used acupuncture points will be documented. The patients difficulties will be observed and their medication and will be recorded in the patient diary.\n\nPossible skin toxicities wil be documented by the photography.\n\nBefore the randomization, all subjects will sign the voluntary informed consent. After the achievement of 50 enrolled subjects in any regimen, the enrollment will continue only to the other regimen.\n\nHead and neck cancer therapy will include only curative and adjuvant radiotherapy.'}, 'conditionsModule': {'conditions': ['Malignant Tumor of Soft Tissue of Head, Face and Neck']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Regimen A', 'type': 'ACTIVE_COMPARATOR', 'description': 'Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.', 'interventionNames': ['Drug: Standard supportive therapy']}, {'label': 'Regimen B', 'type': 'EXPERIMENTAL', 'description': 'Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.', 'interventionNames': ['Other: Acupuncture', 'Drug: Standard supportive therapy']}], 'interventions': [{'type': 'OTHER', 'name': 'Acupuncture', 'description': 'Schedule of the acupuncture:\n\nAcupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.\n\nAcupuncture will be performed by a physician trained in acupuncture.', 'armGroupLabels': ['Regimen B']}, {'type': 'DRUG', 'name': 'Standard supportive therapy', 'description': 'Standard supportive therapy', 'armGroupLabels': ['Regimen A', 'Regimen B']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Management of acute toxicity of radiotherapy with acupuncture: Reducing the grade of acute toxicity in radiotherapy', 'description': 'Reducing the grade of acute toxicity in radiotherapy.', 'timeFrame': 'six months after the end of radiotherapy'}], 'secondaryOutcomes': [{'measure': 'Management of chronic toxicity of radiotherapy with acupuncture: Lower incidence of chronic toxicity of radiotherapy', 'description': 'Lower incidence of chronic toxicity of radiotherapy.', 'timeFrame': 'six months after the end of radiotherapy'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Curative and adjuvant radiotherapy for head and neck tumors;\n* PS 1-2;\n* Patient collaboration in evaluation of the toxicity diary.\n\nExclusion Criteria:\n\n* Palliative radiotherapy in the head and neck tumor;\n* PS 3;\n* Non-compliance of the patient.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Renata Hejnov, Msc', 'role': 'CONTACT', 'phone': '+42054313', 'phoneExt': '6232', 'email': 'renata.hejnova@mou.cz'}, {'name': 'Regina Demlov, MD,Ph.D.', 'role': 'CONTACT', 'email': 'demlova@mou.cz'}], 'locations': [{'facility': 'Masaryk Memorial Cancer Institute', 'status': 'RECRUITING', 'city': 'Brno', 'zip': '65653', 'country': 'Czechia', 'contacts': [{'name': 'Radana Dymkov, MD', 'role': 'CONTACT', 'phone': '+42054313', 'phoneExt': '1130', 'email': 'radana.dymackova@mou.cz'}], 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}]}, 'referencesModule': {'references': [{'pmid': '22072272', 'type': 'BACKGROUND', 'citation': 'Meng Z, Garcia MK, Hu C, Chiang J, Chambers M, Rosenthal DI, Peng H, Zhang Y, Zhao Q, Zhao G, Liu L, Spelman A, Palmer JL, Wei Q, Cohen L. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer. 2012 Jul 1;118(13):3337-44. doi: 10.1002/cncr.26550. Epub 2011 Nov 9.'}, {'pmid': '21537645', 'type': 'BACKGROUND', 'citation': 'Braga FP, Lemos Junior CA, Alves FA, Migliari DA. Acupuncture for the prevention of radiation-induced xerostomia in patients with head and neck cancer. Braz Oral Res. 2011 Mar-Apr;25(2):180-5. doi: 10.1590/s1806-83242011000200014.'}, {'pmid': '32597419', 'type': 'DERIVED', 'citation': 'Dymackova R, Kazda T, Slavik M, Selingerova I, Slampa P, Slama O. Acupuncture in the treatment of acute toxicity during and after head and neck cancer radiotherapy: Interim analysis of randomized prospective open-label trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):454-460. doi: 10.5507/bp.2020.021. Epub 2020 Jun 18.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019066', 'term': 'Facies'}], 'ancestors': [{'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D015670', 'term': 'Acupuncture Therapy'}], 'ancestors': [{'id': 'D000529', 'term': 'Complementary Therapies'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}",False
"{'identificationModule': {'nctId': 'NCT05653622', 'orgStudyIdInfo': {'id': '2021-010'}, 'organization': {'fullName': 'Institut de cancrologie Strasbourg Europe', 'class': 'OTHER'}, 'briefTitle': 'Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma', 'officialTitle': 'Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma', 'acronym': 'SIB-DOPA'}, 'statusModule': {'statusVerifiedDate': '2025-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-06-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-07-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2029-07-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-11-28', 'studyFirstSubmitQcDate': '2022-12-07', 'studyFirstPostDateStruct': {'date': '2022-12-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-25', 'lastUpdatePostDateStruct': {'date': '2025-12-03', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Institut de cancrologie Strasbourg Europe', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall survival (OS) ranged from 15 to 18 months.\n\nSome frail patients received hypofractionated radiation and concomitant and adjuvant TMZ. For some, the radiation dose is not optimal. Moreover, recurrences develop mainly in the initial tumor site. These two reasons justify increasing the dose. To limit the movements of these fragile patients, the method consists of increasing the dose without increasing the number of sessions by using the Simultaneous Integrated Boost (SIB) which increases the dose in targeted volumes while the rest of the volume receives a minimum dose. A phase I trial showed the possibility of increasing the dose in SIB up to 80 Gy in a part of the GBM enhanced on MRI.\n\nFDOPA PET detects certain more aggressive tumor areas, areas likely to recur. Integrating them into the SIB seems appropriate. A phase II trial showed the interest of SIB guided by FDOPA PET in terms of progression-free survival but without impact on OS. This study differed from the one the investigators propose, because a dose and conventional fractionation, identical to that of the European Organization for Research and Treatment of Cancer/National Cancer Information Center (NCIC/EORTC) protocol were delivered, the gliomas were unmethylated MGMT, less likely to respond. Studies with SIB and hypofractionation are often retrospective and for others, hypofractionation was debatable and the dose increase was not based on PET capture but on MRI. However, a prospective phase II study, with SIB and hypofractionation, not integrating FDopa PET has demonstrated the relevance of SIB.\n\nIn this project, the investigators propose to use the integrated boost technique (SIB) guided by PET FDOPA to increase the radiation dose in GBM, in patients either fragile and partially operated, or only biopsied and for whom the prognosis is the most pejorative.'}, 'conditionsModule': {'conditions': ['Glioblastoma Multiforme, Adult'], 'keywords': ['glioblastoma', 'intensity modulated radiation therapy', '18F-DOPA-PET imaging']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'SIB-DOPA', 'type': 'EXPERIMENTAL', 'interventionNames': ['Procedure: Integrated boost technique (SIB) guided by PET FDOPA']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Integrated boost technique (SIB) guided by PET FDOPA', 'description': 'intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy', 'armGroupLabels': ['SIB-DOPA']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival (OS)', 'description': 'Evaluate the overall survival (OS) of patients with glioblastoma treated with integrated boost (SIB) with increased dose guided by FDOPA PET', 'timeFrame': 'At 24 months after inclusion'}], 'secondaryOutcomes': [{'measure': 'Progression-Free Survival (PFS)', 'description': 'To assess the progression-free survival (PFS) of patients with glioblastoma treated with SIB with increased dose guided by FDOPA PET', 'timeFrame': 'At 24 months after inclusion'}, {'measure': 'Sites of progression: distant, marginal or in-field progression', 'description': 'The progression will be defined by its location by comparing the progression imaging with that used for dosimetry. It will be considered ""distant"" if it develops beyond the 95% isodose, ""marginal"" if it cuts the 95% isodose and ""in-field"" if it is completely within the 95% isodose. The 95% isodose is the reference isodose for the prescription of hypofractionated radiotherapy.', 'timeFrame': 'At the date of progression, assessed up to 24 months'}, {'measure': 'Assess the rate of acute complications of grade  3', 'description': 'Acute toxicities are defined as toxicities by the Common Terminology Criteria for Adverse Events (CTCAE v5) occurring within 6 months of the start of radiotherapy.', 'timeFrame': 'At 6 months after the start of radiotherapy'}, {'measure': 'Characterize the PET parameters during progression', 'description': 'PET Parameters:\n\n* Standardized Uptake Value (SUV) max tumor, SUV max tumor/healthy tissue, SUV max T/striatum\n* SUV mean tumor, SUV mean tumor/healthy tissue, SUV mean T/striatum', 'timeFrame': 'At the date of progression, assessed up to 24 months'}, {'measure': 'Evolution of the PET parameters', 'description': 'PET Parameters:\n\n* Standardized Uptake Value (SUV) max tumor, SUV max tumor/healthy tissue, SUV max T/striatum\n* SUV mean tumor, SUV mean tumor/healthy tissue, SUV mean T/striatum', 'timeFrame': 'Change between baseline and the date of progression, assessed up to 24 months'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)', 'description': 'The quality of life will be measured at the inclusion with Quality of Life Questionnaire-C30 (Cancer 30items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)', 'description': 'The quality of life will be measured at the inclusion with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)', 'description': 'The quality of life will be measured at 3 months with Quality of Life Questionnaire-C30 (Cancer 30items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 3 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)', 'description': 'The quality of life will be measured at 3 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 3 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)', 'description': 'The quality of life will be measured at 6 months with Quality of Life Questionnaire-C30 (Cancer 30items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 6 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)', 'description': 'The quality of life will be measured at 6 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 6 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)', 'description': 'The quality of life will be measured at 12 months with Quality of Life Questionnaire-C30 (Cancer 30items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 12 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)', 'description': 'The quality of life will be measured at 12 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 12 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)', 'description': 'The quality of life will be measured at 18 months with Quality of Life Questionnaire-C30 (Cancer 30items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 18 months after inclusion'}, {'measure': 'Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)', 'description': 'The quality of life will be measured at 18 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items).\n\nAll items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At 18 months after inclusion'}, {'measure': 'Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and Overall survival', 'description': 'MGMT promoter methylation status (binary variable, determined by either Polymerase Chain reaction (PCR) or immunohistochemistry)', 'timeFrame': 'At 24 months after inclusion'}, {'measure': 'Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and Progression-Free Survival', 'description': 'MGMT promoter methylation status (binary variable, determined by either PCR or immunohistochemistry)', 'timeFrame': 'At 24 months after inclusion'}, {'measure': 'Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and acute toxicities', 'description': 'MGMT promoter methylation status (binary variable, determined by either PCR or immunohistochemistry)', 'timeFrame': 'At 24 months after inclusion'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Unfit patient without indication to the STUPP protocol :\n\nCohort 1 : Non-operable patients and  18 years old or  70 years old and Karnofsky Index (KI)  50% on inclusion AND Result of a biopsy available Cohort 2 : Patients \\> 70 years old and Balducci score I or II and KI  60% on inclusion AND Partial resection (defined on the remnographic criteria of postoperative MRI) OR biopsy result available\n\n* Histologically proven glioblastoma\n* Increased metabolism of amino acids in PET FDOPA allowing contouring the Biological Target Volume (BTV)\n\nExclusion Criteria:\n\n* Patients with an indication for irradiation according to the STUPP protocol (fit patient)\n* Patient with a contraindication to MRI or PET\n* Limit of the provisional target volume or Planning target volume (PTV), second PTV \\< 2 cm from the chiasm and the optic nerves\n* Absence of uptake of FDopa', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Manon VOEGELIN', 'role': 'CONTACT', 'phone': '+33(0)368339523', 'email': 'm.voegelin@icans.eu'}, {'name': 'claire vit', 'role': 'CONTACT', 'phone': '+33(0)368339523', 'email': 'c.vit@icans.eu'}], 'overallOfficials': [{'name': 'Caroline BUND', 'affiliation': 'Institut de cancrologie Strasbourg Europe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'ICANS', 'status': 'RECRUITING', 'city': 'Strasbourg', 'country': 'France', 'contacts': [{'name': 'Caroline BUND', 'role': 'CONTACT', 'phone': '0368766767', 'email': 'c.bund@icans.eu'}], 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'ICL', 'status': 'RECRUITING', 'city': 'Vanduvre-ls-Nancy', 'country': 'France', 'contacts': [{'name': 'Nicolas DEMOGEOT', 'role': 'CONTACT', 'phone': '03 83 59 85 74', 'email': 'n.demogeot@nancy.unicancer.fr'}], 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}]}, 'referencesModule': {'references': [{'pmid': '28296618', 'type': 'BACKGROUND', 'citation': ""Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.""}, {'pmid': '27117900', 'type': 'BACKGROUND', 'citation': 'Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau E, Maingon P, Noel G. A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer Radiother. 2016 May;20(3):193-8. doi: 10.1016/j.canrad.2015.12.005. Epub 2016 Apr 23.'}, {'pmid': '33023662', 'type': 'BACKGROUND', 'citation': 'Somme F, Bender L, Namer IJ, Noel G, Bund C. Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. Cancer Imaging. 2020 Oct 6;20(1):70. doi: 10.1186/s40644-020-00348-5.'}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005909', 'term': 'Glioblastoma'}], 'ancestors': [{'id': 'D001254', 'term': 'Astrocytoma'}, {'id': 'D005910', 'term': 'Glioma'}, {'id': 'D018302', 'term': 'Neoplasms, Neuroepithelial'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}]}}",False
"{'identificationModule': {'nctId': 'NCT07142122', 'orgStudyIdInfo': {'id': 'TLPG-CBVP'}, 'secondaryIdInfos': [{'id': '2023-2839', 'type': 'OTHER_GRANT', 'domain': 'Fujian Provincial Young and Middle-aged Health Leading Talent Training Program'}], 'organization': {'fullName': 'Fujian Cancer Hospital', 'class': 'OTHER_GOV'}, 'briefTitle': 'Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial', 'officialTitle': 'Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial', 'acronym': 'TLPG-CBVP'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-01-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2029-01-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-08-19', 'studyFirstSubmitQcDate': '2025-08-25', 'studyFirstPostDateStruct': {'date': '2025-08-26', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-08-25', 'lastUpdatePostDateStruct': {'date': '2025-08-26', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Fujian Cancer Hospital', 'class': 'OTHER_GOV'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This prospective, single-center, randomized, controlled, non-inferiority clinical trial aims to compare the safety and postoperative quality of life of early upper gastric cancer patients undergoing total laparoscopic proximal gastrectomy (TLPG) with preservation of both the hepatic and celiac branches of the vagus nerve versus preservation of the hepatic branch only. The primary endpoint is gastric emptying half-time of solid food at 6 months after surgery. Secondary outcomes include incidence of reflux esophagitis, quality of life scores (EORTC QLQ-C30/STO22), number and positivity rate of lymph nodes retrieved, and 3-year disease-free survival. The study will provide evidence for optimizing minimally invasive surgical strategies for early upper gastric cancer.', 'detailedDescription': 'Early gastric cancer involving the upper third of the stomach or esophagogastric junction is increasingly managed with minimally invasive surgery. The vagus nerve plays an essential role in regulating gastric motility and postoperative physiological recovery. Preservation of the hepatic branch is widely accepted, while the role of preserving the celiac branch remains controversial. This trial is designed to evaluate whether preservation of the celiac branch during TLPG improves gastric emptying and postoperative quality of life without compromising oncological safety. Eligible patients (cT1bN0M0, tumor size 4 cm, no prior chemotherapy/radiotherapy) will be randomized into two groups: Group A (hepatic and celiac branches preserved) and Group B (hepatic branch preserved only). Both groups undergo double-tract reconstruction. The study will enroll 76 patients (38 per group) with sufficient statistical power. Outcomes will be analyzed using standard statistical methods, and the findings are expected to provide evidence for refined vagus-nerve-preserving surgery in early gastric cancer.'}, 'conditionsModule': {'conditions': ['Gastric Cancer'], 'keywords': ['Esophagogastric Junction Adenocarcinoma']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 76, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Experimental Arm (Group A)', 'type': 'EXPERIMENTAL', 'description': 'Total laparoscopic proximal gastrectomy with preservation of hepatic and celiac branches of the vagus nerve. Reconstruction by double-tract anastomosis.', 'interventionNames': ['Procedure: Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction.']}, {'label': 'Active Comparator Arm (Group B)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Procedure: Total laparoscopic proximal gastrectomy with preservation of hepatic branch but without preservation of the celiac branch of the vagus nerve. Reconstruction by double-tract anastomosis.', 'interventionNames': ['Procedure: Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction.', 'description': 'Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via fenestration of the lesser omentum) and the celiac branch (via skeletonization of the left gastric artery). The esophagus was transected 3 cm proximal to the tumor, preserving \\>50% of the residual stomach. Double-tract reconstruction was then performed: an end-to-side esophagojejunostomy was created first, followed by a side-to-side gastrojejunostomy between the residual stomach and jejunum, and finally a side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This approach achieves oncological resection while maximizing preservation of digestive physiology (gallbladder contraction, reduced dumping syndrome, and partial gastric reservoir function).', 'armGroupLabels': ['Experimental Arm (Group A)']}, {'type': 'PROCEDURE', 'name': 'Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.', 'description': 'Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via lesser omentum fenestration adjacent to the liver edge), while deliberately not preserving the celiac branch (by direct transection at the root of the left gastric artery). The esophagus was transected 3 cm proximal to the tumor with preservation of \\>50% gastric remnant. Double-tract reconstruction was then executed: end-to-side esophagojejunostomy (circular stapler)  side-to-side gastrojejunostomy (linear cutter)  side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This technique achieves oncological resection while utilizing the residual stomach and dual-pathway design to minimize postoperative dumping syndrome and preserve partial gastric function.', 'armGroupLabels': ['Active Comparator Arm (Group B)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Gastric half-emptying time of solid food at 6 months postoperatively (minutes, measured by gastric emptying test)', 'timeFrame': '6 months post-operation'}], 'secondaryOutcomes': [{'measure': 'Reflux Esophagitis (LA Classification)', 'timeFrame': '1,3,6,12,24 months'}, {'measure': 'EORTC QLQ-C30/STO22 Scores', 'timeFrame': '1,3,6,12,24 months'}, {'measure': 'Lymph Node Yield/Positivity Rate', 'timeFrame': 'Intraoperative'}, {'measure': '3-Year Disease-Free Survival', 'timeFrame': '36 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma (papillary, tubular, mucinous, poorly cohesive including signet-ring cell carcinoma, or mixed type).\n3. Primary tumor located in the upper third of the stomach, or esophagogastric junction cancer with tumor size 4 cm.\n4. Clinical stage cT1bN0M0 without lymph node metastasis.\n5. BMI \\<30 kg/m.\n6. No history of upper abdominal surgery (except laparoscopic cholecystectomy).\n7. No prior chemotherapy, radiotherapy, targeted therapy, or immunotherapy.\n8. ECOG performance status 0-1.\n9. ASA class I-III.\n10. Adequate organ function.\n11. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding.\n2. Other malignancies within 5 years.\n3. Active infection requiring systemic therapy or fever 38C preoperatively.\n4. Severe psychiatric illness.\n5. Severe respiratory disease.\n6. Severe hepatic or renal dysfunction.\n7. Unstable angina or myocardial infarction within 6 months.\n8. Stroke or intracranial hemorrhage within 6 months.\n9. Long-term systemic glucocorticoid therapy within 1 month (local use excluded).\n10. Complications of gastric cancer (bleeding, perforation, obstruction).\n11. Participation in another clinical study within 6 months.\n\nExclusion During Study (Removal Criteria):\n\nR0 resection not achieved, change of procedure to total gastrectomy or PPG, combined surgery for other diseases, severe perioperative complications, emergency surgery required, patient withdrawal of consent, or protocol violation.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Zaisheng Ye, doctoral', 'role': 'CONTACT', 'phone': '+86 591 13950203076', 'email': 'flyingengel@sina.com'}], 'locations': [{'facility': ""420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province"", 'status': 'RECRUITING', 'city': 'Fuzhou', 'state': 'Fujian', 'zip': '350014', 'country': 'China', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}]}}",,,"{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013274', 'term': 'Stomach Neoplasms'}], 'ancestors': [{'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}]}}",False
